These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 30125635)

  • 21. A method to estimate composite doses for organs at risk in prostate cancer patients treated with EBRT in combination with HDR BT.
    Pettersson N; Johansson KA; Alsadius D; Tucker SL; Steineck G; Olsson C
    Acta Oncol; 2014 Jun; 53(6):815-21. PubMed ID: 24460070
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Radiation dose escalation for localized prostate cancer: intensity-modulated radiotherapy versus permanent transperineal brachytherapy.
    Wong WW; Vora SA; Schild SE; Ezzell GA; Andrews PE; Ferrigni RG; Swanson SK
    Cancer; 2009 Dec; 115(23):5596-606. PubMed ID: 19670452
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Intensity-modulated radiation therapy (IMRT) for prostate cancer with the use of a rectal balloon for prostate immobilization: acute toxicity and dose-volume analysis.
    Teh BS; Mai WY; Uhl BM; Augspurger ME; Grant WH; Lu HH; Woo SY; Carpenter LS; Chiu JK; Butler EB
    Int J Radiat Oncol Biol Phys; 2001 Mar; 49(3):705-12. PubMed ID: 11172952
    [TBL] [Abstract][Full Text] [Related]  

  • 24. ASCENDE-RT: An Analysis of Treatment-Related Morbidity for a Randomized Trial Comparing a Low-Dose-Rate Brachytherapy Boost with a Dose-Escalated External Beam Boost for High- and Intermediate-Risk Prostate Cancer.
    Rodda S; Tyldesley S; Morris WJ; Keyes M; Halperin R; Pai H; McKenzie M; Duncan G; Morton G; Hamm J; Murray N
    Int J Radiat Oncol Biol Phys; 2017 Jun; 98(2):286-295. PubMed ID: 28433432
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Rates of rectal toxicity in patients treated with high dose rate brachytherapy as monotherapy compared to dose-escalated external beam radiation therapy for localized prostate cancer.
    Parzen JS; Ye H; Gustafson G; Yan D; Martinez A; Chen PY; Ghilezan M; Sebastian E; Limbacher A; Krauss DJ
    Radiother Oncol; 2020 Jun; 147():123-129. PubMed ID: 32276193
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Incidence of and factors related to late complications in conformal and conventional radiation treatment of cancer of the prostate.
    Schultheiss TE; Hanks GE; Hunt MA; Lee WR
    Int J Radiat Oncol Biol Phys; 1995 Jun; 32(3):643-9. PubMed ID: 7790250
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Propensity score-matched analysis comparing dose-escalated intensity-modulated radiation therapy versus external beam radiation therapy plus high-dose-rate brachytherapy for localized prostate cancer.
    Tamihardja J; Lawrenz I; Lutyj P; Weick S; Guckenberger M; Polat B; Flentje M
    Strahlenther Onkol; 2022 Aug; 198(8):735-743. PubMed ID: 35551434
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact of High-Dose-Rate and Low-Dose-Rate Brachytherapy Boost on Toxicity, Functional and Cancer Outcomes in Patients Receiving External Beam Radiation Therapy for Prostate Cancer: A National Population-Based Study.
    Parry MG; Nossiter J; Sujenthiran A; Cowling TE; Patel RN; Morris M; Berry B; Cathcart P; Clarke NW; Payne H; van der Meulen J; Aggarwal A
    Int J Radiat Oncol Biol Phys; 2021 Apr; 109(5):1219-1229. PubMed ID: 33279595
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Role of principal component analysis in predicting toxicity in prostate cancer patients treated with hypofractionated intensity-modulated radiation therapy.
    Vesprini D; Sia M; Lockwood G; Moseley D; Rosewall T; Bayley A; Bristow R; Chung P; Ménard C; Milosevic M; Warde P; Catton C
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):e415-21. PubMed ID: 21477939
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Relationships between dose to the gastro-intestinal tract and patient-reported symptom domains after radiotherapy for localized prostate cancer.
    Thor M; Olsson CE; Oh JH; Petersen SE; Alsadius D; Bentzen L; Pettersson N; Muren LP; Waldenström AC; Høyer M; Steineck G; Deasy JO
    Acta Oncol; 2015; 54(9):1326-34. PubMed ID: 26340136
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Colorectal complications of external beam radiation versus brachytherapy for prostate cancer.
    Lesperance RN; Kjorstadt RJ; Halligan JB; Steele SR
    Am J Surg; 2008 May; 195(5):616-20; discussion 620. PubMed ID: 18374892
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of toxicities between ultrahypofractionated radiotherapy versus brachytherapy with or without external beam radiotherapy for clinically localized prostate cancer.
    Yamazaki H; Masui K; Suzuki G; Aibe N; Shimizu D; Kimoto T; Yamada K; Ueno A; Matsugasumi T; Yamada Y; Shiraishi T; Fujihara A; Yoshida K; Nakamura S
    Sci Rep; 2022 Mar; 12(1):5055. PubMed ID: 35322160
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Late toxicity after single dose HDR prostate brachytherapy and EBRT for localized prostate cancer: Clinical and dosimetric predictors in a prospective cohort study.
    Büchser D; Casquero F; Espinosa JM; Perez F; Minguez P; Martinez-Indart L; Suarez F; Gonzalez A; Cacicedo J; San Miguel I; Maleta A; Gomez-Caamaño A; Bilbao P; Gomez-Iturriaga A
    Radiother Oncol; 2019 Jun; 135():13-18. PubMed ID: 31015158
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Preliminary toxicity analysis of 3-dimensional conformal radiation therapy versus intensity modulated radiation therapy on the high-dose arm of the Radiation Therapy Oncology Group 0126 prostate cancer trial.
    Michalski JM; Yan Y; Watkins-Bruner D; Bosch WR; Winter K; Galvin JM; Bahary JP; Morton GC; Parliament MB; Sandler HM
    Int J Radiat Oncol Biol Phys; 2013 Dec; 87(5):932-8. PubMed ID: 24113055
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of chronic gastrointestinal and genitourinary toxicities between brachytherapy and external beam radiotherapy for patients with prostate cancer: A systematic review and meta-analysis.
    Li X; Shan L; Wang Q; Zhai H; Xuan Y; Yan G
    Technol Health Care; 2023; 31(S1):357-372. PubMed ID: 37066936
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Accumulation of rectum dose-volume metrics for prostate external beam radiotherapy combined with brachytherapy: Evaluating deformably registered dose distribution addition using parameter-based addition.
    Moulton CR; House MJ; Lye V; Tang CI; Krawiec M; Joseph DJ; Denham JW; Ebert MA
    J Med Imaging Radiat Oncol; 2017 Aug; 61(4):534-542. PubMed ID: 28185419
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Predictive modelling for late rectal and urinary toxicities after prostate radiotherapy using planned and delivered dose.
    Ong ALK; Knight K; Panettieri V; Dimmock M; Tuan JKL; Tan HQ; Wright C
    Front Oncol; 2022; 12():1084311. PubMed ID: 36591496
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Periodical assessment of genitourinary and gastrointestinal toxicity in patients who underwent prostate low-dose-rate brachytherapy.
    Tanaka N; Asakawa I; Anai S; Hirayama A; Hasegawa M; Konishi N; Fujimoto K
    Radiat Oncol; 2013 Jan; 8():25. PubMed ID: 23363647
    [TBL] [Abstract][Full Text] [Related]  

  • 39. High-dose-rate brachytherapy monotherapy versus low-dose-rate brachytherapy with or without external beam radiotherapy for clinically localized prostate cancer.
    Yamazaki H; Masui K; Suzuki G; Nakamura S; Yamada K; Okihara K; Shiraishi T; Yoshida K; Kotsuma T; Tanaka E; Otani K; Yoshioka Y; Ogawa K
    Radiother Oncol; 2019 Mar; 132():162-170. PubMed ID: 30416045
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The burden of overtreatment: comparison of toxicity between single and combined modality radiation therapy among low risk prostate cancer patients.
    Jiang R; Tomaszewski JJ; Ward KC; Uzzo RG; Canter DJ
    Can J Urol; 2015 Feb; 22(1):7648-55. PubMed ID: 25694014
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.